Baxdela (Delafloxacin)

Medical Uses: Baxdela (delafloxacin) is a fluoroquinolone antibacterial used for the treatment of adults with the following infections caused by designated susceptible bacteria:

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
• Community-Acquired Bacterial Pneumonia (CABP)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Delafloxacin and other antibacterial drugs, Delafloxacin should be used only for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria.

Recommended Dosage:
Baxdela Tablets:
Administer this medicine at least 2 hours before or 6 hours after antacids containing magnesium, or aluminum, with sucralfate, with metal cations such as iron, or with multivitamin preparations containing zinc or iron, or with didanosine buffered tablets for oral suspension or the pediatric powder for oral solution. Tablets can be taken with or without food.
In case of a missed dose, take it as soon as possible, anytime up to 8 hours before their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.

Baxdela for Injection:
Do not administer Baxdela for Injection with any solution containing multivalent cations, e.g., calcium and magnesium, through the same intravenous line. Do not co-infuse this injection with other medicines.

Recommended Dosage Regimen:

• For ABSSSI: The recommended dosage of Baxdela is 300 mg administered by IV (60-minute drip) every 12 hours for 5 to 14 days.
• For CABP: The recommended dosage of Baxdela is 300 mg administered by IV every 12 hours (60-minute drip), and your doctor may switch you to a 450 mg tablet every 12 hours, OR you can take the 450 mg tablet every 12 hours from the start. Total treatment is 5 to 10 days.

• Delafloxacin may cause rare but severe, disabling, and potentially permanent adverse reactions involving tendons, nerves, and the central nervous system. Discontinue immediately if symptoms occur. Avoid use in patients with a history of such reactions to
• fluoroquinolones and monitor vulnerable individuals closely throughout treatment duration.
  Fluoroquinolones, including Delafloxacin, can cause tendinitis and tendon rupture, especially in older adults, transplant recipients, and corticosteroid users. Symptoms may occur within hours or months after therapy. Stop treatment at the first tendon pain, avoid exertion, and initiate alternative antibiotics to protect overall musculoskeletal health.
• Delafloxacin can lead to sensory or motor nerve damage, causing tingling, burning, numbness, or weakness. These symptoms may arise rapidly and become permanent. Discontinue treatment immediately when neuropathy signs appear and choose an alternative therapy. Early recognition is essential to prevent lasting disability or serious nerve injury.
• Use of this medicine may cause serious CNS effects, including tremors, seizures, hallucinations, anxiety, depression, or confusion. These reactions can occur even after the final dose. Stop treatment if such symptoms develop, and exercise caution in those with CNS disorders, including epilepsy or psychiatric history.
• Delafloxacin may be responsible for worsening muscle weakness in those with myasthenia gravis, potentially causing life-threatening respiratory complications. Do not use it in individuals with a prior history of myasthenia gravis. In case no alternatives exist, monitor closely for worsening weakness and breathing complications and stop treatment immediately upon symptom progression.
• Life-threatening allergic reactions, including angioedema, anaphylaxis, and severe dermatologic reactions, may occur with Delafloxacin treatment. Symptoms may arise after the first dose. Stop immediately in case hypersensitivity arises and avoid re-exposure. Provide emergency management when required and properly monitor patients with prior antibiotic allergies.
• Delafloxacin treatment may increase the risk of aortic aneurysm or dissection, particularly in elderly patients or those with vascular disease. Use it cautiously in these individuals. Educate patients about sudden abdominal, chest, or back pain and stop treatment quickly in case such symptoms occur.
• Use of this drug without a confirmed bacterial infection may promote growth of drug-resistant organisms. Use only when clearly required and based on culture results when possible. Inappropriate use diminishes antibiotic effectiveness, complicates future treatments, and increases the risk of resistant infections across both community and healthcare settings.
• This medicine is recommended during pregnancy because of potential risks to fetal musculoskeletal development. Prescribe only if benefits outweigh risks and no safer alternatives exist. Counsel those who are pregnant about possible side effects and monitor appropriately if exposure is unavoidable during critical treatment situations.

What documents are required to import BAXDELA to India?

BAXDELA (delafloxacin) tablet/injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is BAXDELA available in India?

BAXDELA (delafloxacin tablets/injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Baxdela in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

BAXDELA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of BAXDELA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Baxdela tablet-injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source BAXDELA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Baxdela®?

Delafloxacin is the Generic Name for the trade name drug Baxdela®.

What is the Manufacturer’s Name of Baxdela®?

Baxdela® is manufactured by Melinta Therapeutics.

Is Baxdela approved by the FDA?

Yes. Baxdela is approved by the FDA. date of first approval: June 19, 2017.

What is the dosage and form of Baxdela® supplied?

Baxdela is supplied as 450 mg per tablet for oral use and 300 mg per vial for intravenous infusion only.

What are the most common side effects of Baxdela®?

The most commonly reported side effects of Baxdela® are nausea, diarrhea, transaminase elevations, headache, and vomiting.

How much does Baxdela® Tablet/Injection cost in India?

Baxdela® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Baxdela prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Baxdela Tablet/Injection cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Baxdela® Tablet/Injection be available in SAARC countries?

Apart from Gulf countries, Baxdela® Tablet/Injection can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Baxdela® tablet in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Baxdela® Tablets/Injections online in India?

Yes, one can buy Baxdela tablet-injection online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Baxdela® through legal channels.

What are the storage conditions of Baxdela® Tablets/Injection?

Baxdela® for Injection and Baxdela® Tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).